Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl ~~or naphthyl~~;

m = 0 or 1;

n = 0 or 1;

A is ~~selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H$, $-SO_3H$, $-PO(C_1$-$_3$alkyl)OH and 1*H*-tetrazol-5-yl~~;

R1 and R2 are each independently selected from the group consisting of: hydrogen~~, halo, hydroxy, $-CO_2H$~~ and C_1-$_4$alkyl~~, optionally substituted from one up to the maximum number of substitutable positions with halo~~;

R3 is selected from the group consisting of: hydrogen and C_1-$_4$alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R^4 is independently selected from the group consisting of: halo, C_1-4alkyl and C_1-3alkoxy, said C_1-4alkyl and C_1-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

C is ~~selected from the group consisting of:~~

~~(1) C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or -CHOH-C_{1-6}alkyl, said C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl and -CHOH-C_{1-6}alkyl optionally substituted with phenyl, and~~

~~(2)~~ ~~phenyl or~~ HET, wherein HET is thienyl, ~~each~~ optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl[[,]] and C_1-4alkyl ~~and C_1-4alkoxy~~, said C_1-4alkyl ~~and C_1-4alkoxy groups~~ optionally substituted from one up to the maximum number of substitutable positions with ~~a substituent independently selected from~~ halo ~~and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups,~~

~~or **C** is not present~~; and

~~when **C** is not present then **B** is selected from the group consisting of: phenyl, C_5-16alkyl, C_5-16alkenyl, C_5-16alkynyl, -CHOH-C_4-15alkyl, -CHOH-C_4-15alkenyl, -CHOH-C_4-15alkynyl, C_{4-15}alkoxy, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl,~~

~~when **C** is phenyl or HET then~~ **B** is ~~selected from the group consisting of: C_1-6alkyl,~~ C_1-5alkoxy, ~~-(C=O)-C_{1-5}alkyl, -(C=O)-O-C_{1-4}alkyl, -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl,~~



~~, phenyl and HET, and~~

~~when **C** is C_{1-8}alkyl, C_{1-8}alkoxy, -(C=O)-C_{1-6}alkyl or -CHOH-C_{1-6}alkyl then **B** is phenyl; and~~

~~R^6 and R^7 are independently selected from the group consisting of: hydrogen, C_1-9alkyl and -$(CH_2)_p$-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C_1-3alkyl and C_{1-3}alkoxy, each optionally substituted with 1-3 halo groups.~~

2. (currently amended) The compound according to Claim 1 wherein:

~~Ar is phenyl;~~

the group **–B-C** is attached to the phenyl ring at the 3- or 4-position~~;~~

~~**C** is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C_1-4alkyl and C_1-4alkoxy, said C_1-4alkyl and C_1-4alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups,~~

~~or **C** is not present;~~

~~when **C** is not present then **B** is selected from the group consisting of: C_7-12alkyl, C_7-12alkenyl, C_7-12alkynyl, C_{6-11}alkoxy, -O-C_{6-11}alkenyl, -O-C_{6-11}alkynyl, -(C=O)-C_{6-11}alkyl, -(C=O)-~~

~~C_{6-11}alkenyl, (C=O) C_{6-11}alkynyl, (C=O) O C_{5-10}alkyl, (C=O) O C_{5-19}alkenyl, and (C=O) O C_{5-10}alkynyl and **C** is not present;~~

~~and~~

~~when **C** is phenyl or HET then **B** is selected from the group consisting of C_1-5alkyl, C_{1-4}alkoxy, (C=O) C_{1-4}alkyl, (C=O) O C_{1-3}alkyl, phenyl and HET~~.

3. (canceled)

4. (original) The compound according to Claim 1 wherein m is 0.

5. (original) The compound according to Claim 1 wherein m is 1.

6. (original) The compound according to Claim 1 wherein n is 0.

7. (original) The compound according to Claim 1 wherein n is 1.

8. (canceled)

9. (currently amended) The compound according to Claim 1 wherein:

B is methoxy and **C** is HET, wherein said HET is thienyl substituted with phenyl and C_1-4alkyl, said C_1-4alkyl optionally substituted from one up to the maximum number of substitutable positions with halo~~, and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo and C_{1-4}alkyl, optionally substituted with 1-3 halo groups~~.

10 to 20. (canceled)

21. (currently amended) The compound according to Claim ~~20~~ 4 wherein R^1, R^2 and R^3 are hydrogen.

22. (original) The compound according to Claim 2 wherein the group **–B-C** is attached to the phenyl ring at the 4-position.

23. (canceled)

24. (original) A compound represented by Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n = 0 or 1;

R^3 is selected from the group consisting of: hydrogen and C_{1-4}alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R^4 is independently selected from the group consisting of: halo, C_1-4alkyl and C_1-3alkoxy, said C_1-4alkyl and C_1-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.

25. (original) The compound according to Claim 24 wherein n is 0.

26. (original) The compound according to Claim 24 wherein n is 1.

27. (original) The compound according to Claim 24 wherein R^3 is hydrogen.

28. (currently amended) The compound according to Claim 24 selected from the following table:





or a pharmaceutically acceptable salt of any of the foregoing compounds.

29 to 33. (canceled)

34. (original) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

35 to 47. (canceled)